Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study


Chauhan A1, Samnaliev M2, Ken-Opurum J1, Sai Srinivas S3, Mehta AM1, Dex T4, Charland S5, Revel A4, Preblick R4
1Axtria, Inc., Berkeley Heights, NJ, USA, 2Axtria, Inc., Needham, MA, USA, 3Axtria India Ltd., Secunderabad Telangana, India, 4Sanofi, Bridgewater, NJ, USA, 5SanofiUS, Golden, CO, USA

OBJECTIVES: The fixed -ratio combination of insulin glargine (iGlar) plus lixisenatide (iGlarLixi) has proven efficacious in clinical trials; however, there is limited evidence of its benefits in diverse, real-world patients with type 2 Diabetes Mellitus (T2DM) who present in routine clinical practice.

METHODS: A large integrated claims and EHR database was used to identify two real-world cohorts (ages ≥18) with T2DM who were eligible for treatment with iGlarLixi. At baseline, the first cohort (insulin cohort) received insulins with or without oral antidiabetic drugs (OADs) and the second (OAD only cohort) received OADs only. A Monte Carlo patient-level simulation was applied to each cohort based on treatment strategies and efficacies from LixiLan- L and LixiLan-O trials to estimate reductions in glycated hemoglobin A1C (A1C) and the percentage achieving age-based A1C goals (≤7% for ages <65 and ≤8% for ages ≥65) at 30 weeks.

RESULTS: The real-world insulin (N=3,797) and OAD only (N=17,633) cohorts differed considerably in demographics, age, clinical characteristic, baseline A1C levels, and background OAD therapies compared to the populations in the Lixilan-L and Lixilan-O trials. Notwithstanding, in the insulin cohort simulation, A1C goals were achieved among 52.6% vs. 31.6% (p<0.001) of patients in the iGlarLixi vs. the iGlar arms, respectively and in the OAD only cohort simulation, A1C goals were achieved among 59.9% vs. 49.3% and 32.8% (p<0.001) of patients in the iGlarLixi vs. the iGlar, and lixisenatide arms, respectively.

CONCLUSIONS: In this patient-level simulation applied to real-world T2DM patient cohorts with different treatments at baseline, iGlarLixi was associated with greater improvement in A1C levels compared to iGlar or lixisenatide alone, suggesting that the benefits of iGlarLixi extend to clinically diverse real-world populations.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Clinical Outcomes, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy, Decision Modeling & Simulation, Electronic Medical & Health Records


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now